Renovaro Inc. (2Q5)
XSTU 
Summary
2Q5 Chart
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector.
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Application No. 18/058,752).
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged.
Renovaro Inc. Dividends
Renovaro Inc. Earnings
| 29 Sep 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | 0 EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Jul 2024 Date | | - Cons. EPS | - EPS |
| 29 Sep 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | 0 EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Jul 2024 Date | | - Cons. EPS | - EPS |
Renovaro Inc. (2Q5) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Renovaro Inc. ever had a stock split?
Renovaro Inc. Profile
| Biotechnology Industry | Healthcare Sector | David H. Weinstein CEO | XSTU Exchange | US29350E1047 ISIN |
| US Country | 25 Employees | - Last Dividend | - Last Split | 2 Feb 2015 IPO Date |
Overview
Renovaro Inc. is a pioneering pre-clinical stage biotechnology entity focused on the development of novel pharmaceutical and biological therapies aimed at the treatment of critical illnesses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and various forms of cancer within the United States. Formerly known as Renovaro Biosciences Inc., the company underwent a rebranding in February 2024, marking a significant milestone in its evolution. Positioned strategically in Los Angeles, California, Renovaro Inc. collaborates closely with leading institutions such as the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross to leverage groundbreaking scientific research and development initiatives.
Products and Services
- RENB-HV-01
- RENB-HV-12
- RENB-HB-01
- RENB-DC-11
- RENB-DC-12-XX
- RENB-HV-21
An autologous HIV curative treatment in development that aims to provide a personalized approach to HIV eradication, leveraging the patient's own cells to combat the virus.
A therapeutic HIV vaccine designed to elicit a robust immune response against the HIV virus, potentially altering the course of treatment for those living with this chronic condition.
A gene therapy curative treatment targeting the hepatitis B virus, employing advanced gene-editing techniques to potentially cure HBV at the genetic level.
An allogeneic dendritic cell therapeutic vaccine for pancreatic cancer, this product focuses on stimulating the immune system to recognize and destroy pancreatic cancer cells.
Similar to RENB-DC-11, this allogeneic dendritic cell therapeutic vaccine targets other solid tumors, offering hope for the treatment of various types of cancer with a single approach.
A sophisticated treatment combining allogeneic natural killer (NK) and gamma delta T-cells to target HIV, this product represents an innovative approach to enhancing the body's natural defense mechanisms against the virus.
Contact Information
